ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) ...

Real estate agent Kirsten Jordan breaks down the latest trends in the housing market, near-record home sale cancellations in April and her outlook on mortgage rates. Myasthenia gravis is a rare, ...

Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization in the United States ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

As such, UCB’s recently-debuted, U.S.-based DTC rare-disease campaign Imagine Your Zillions supports its gMG treatment Zilbrysq. The effort is based on flipping the preconceived notions associated ...

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of ...

yahoo.com A 21 year old woman with no past medical history presented to the emergency room (ER) with signs and symptoms of sepsis and subsequently went into acute respiratory failure. She was found to ...

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

RETHINKING THE FOUNDATIONS OF MYASTHENIA GRAVIS: WHEN TO TREAT, HOW TO TREAT, AND WHY IT MATTERS Stephen Reddel, University of Sydney, Australia, opened the session by reframing the treatment ...